In our research, we looked at possible differences in the inhibitory actions of Fx and Fxol on components of the NF-κB pathway between estrogen sensitive MCF-7 and estrogen resistant MDA-MB-231 breast cancer cell lines. This evidence concerns the gene NFKB1 and breast carcinoma.